‹ Back
Retatrutide
How it works
Retatrutide pulls three levers at once: glucagon to burn liver fat and raise energy use, GIP to store fat safely and calm nausea, and GLP-1 to quiet hunger and steady insulin.
Sources
Read the original sources
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. (Coskun · 2022 · Abstract; full methods not assumed · checked 2026-10-13)
- Shared mechanistic pathways of glucagon signalling in obesity and fatty liver, Neff 2025, Diabetes Obes Metab (Abstract · checked 2026-10-13)
- Type 2 diabetes and obesity: the present and future of incretin therapy, Shestakova and Bashlykova 2025, Therapeutic Archive (Russia) (Summary · checked 2026-10-13)
- A contemporary rationale for GIP receptor agonism in obesity, Samms 2025, Diabetes (Abstract · checked 2026-10-13)
- Semaglutide lowers body weight in rodents via distributed neural pathways (2020 · Abstract; rodent mechanism · checked 2026-10-13)